Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2008. The report details a corporate action regarding the cancellation of Treasury shares authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital structure.
- Treasury Shares Cancelled: 20,000,000 Ordinary shares of 25 pence each.
- Treasury Shares Remaining: 484,194,158 shares.
- Treasury Share Percentage: 8.93% of total voting rights.
- Shares in Issue: 5,420,033,050 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Treasury share holding by 20,000,000 shares on March 28, 2008. Consequently, the total number of shares in issue remains 5,420,033,050, which serves as the denominator for calculating shareholder notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated total share count of 5,420,033,050 for compliance with disclosure thresholds.
- Confirm the remaining Treasury share balance of 484,194,158 represents 8.93% of voting rights.
- Note that this filing does not contain financial performance data for the period.